MARIO NIEPEL

Mario is Senior Vice President of Translational Sciences at Anavo, and he is the first member of Anavo’s US site located in Cambridge, MA. Mario has a deep understanding of the preclinical development of small molecule inhibitors and degraders, and he has led multiple cross-functional programs to development candidate status and clinical trials in oncology and inflammatory disease. Prior to joining Anavo, Mario held leadership positions at Ribon Therapeutics, Flagship Labs, and Harvard Medical School. He holds graduate degrees in Molecular Biology, Biochemistry, and Cell Biology from the RWTH Aachen, UC Riverside, and Rockefeller University.